Managing your weight and health is a journey, and we understand how frustrating it can be when promising treatments like Wegovy (semaglutide) or Zepbound (tirzepatide) are out of reach. With shortages and high costs, it’s tempting to consider other options, like compounded GLP-1 medications. But here’s why that’s a risky path you should avoid.  The
Read Article

The anti-obesity medication Wegovy® has been approved by the US Food and Drug Administration (FDA) for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity
Read Article